Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

pany is confident that it is making

progress toward fully resolving the production issues that emerged in

mid-2007. In addition, the FDA has accepted the company's responses

to the warning letter issued last year.

-- Total revenue for the Diagnostics/Genetics business is expected to

reach $475-$485 million this year, compared with $411 million in 2007.

The Genetics business has been experiencing particularly strong growth,

driven by an increasing demand for diagnostic testing services. Genzyme

is investing in additional information technology and infrastructure to

continue to strengthen the competitive advantages the Genetics unit has

created.

-- Sales of Aldurazyme are expected to increase to $135-$145 million this

year, compared with $123 million in 2007. Genzyme will record sales of

Aldurazyme and make tiered payments to BioMarin on worldwide product

sales. These payments will be recorded as a cost of goods sold.

Gross Margin

-- Genzyme's recognition of Aldurazyme revenue and the associated payments

to BioMarin will reduce the gross margin by approximately 1 percentage

point without any net impact on the bottom line. The non-GAAP gross

margin for 2008 is expected to be approximately 77 percent of revenue.

Expenses

-- Non-GAAP selling, general and administrative expenses are expected to

represent approximately 27 percent of revenue in 2008, consistent with

SG&A expenses in 2007. SG&A spending reflects the integration of

Bioenvision and the European rollout of Clolar, the ongoing

introduction of Myozyme, the sales force expansion associated with the

launch of Renvela, and the expanded U.S. sales effort for Sepra(R)

products.

-- Non-GAAP research and development spending is expected to represent

approximately 17 perce
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 West Hollywood cosmetic dentist ... for Invisalign. This special offer includes a free consultation ... determine their candidacy for the procedure and answer any ... may also be eligible for the Summer Invisalign special, ... the month of August, patients who choose Invisalign will ...
(Date:9/2/2014)... Dennis Thompson HealthDay Reporter ... early or at low birth weight are at risk later ... problems that increase their risk for heart disease, according to ... children face potential lifetime disadvantages, researchers in both studies ... found that these obstacles can be overcome. Education appeared ...
(Date:9/2/2014)... 02, 2014 Moroccan Eco-Biologics’ new one-of-a-kind ... formulated, while preserving the foundation of all natural Moroccan ... and scalp problems. There is nothing similar to Vitality ... , Hair loss is a commonly encountered problem for ... for treatment have been limited to existing medications offering ...
(Date:9/2/2014)... 02, 2014 USARAD Holdings Inc. ... telemedicine solutions provider, including SecondOpinions.com® – consumer division ... technologically advanced services. The telemedicine industry pioneer is ... Kuwait. , Founded and established in 1963 as ... Shifa began as a maternity care hospital with ...
(Date:9/2/2014)... 02, 2014 The global market for ... million by 2020, growing at an estimated CAGR of ... study by Grand View Research, Inc. Peripheral vascular devices ... devices are used for treating peripheral arterial or coronary ... plaques in arteries. These devices are used to decrease ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5
... who wear bifocal lenses to help them focus accurately may ... new research from Cardiff University. , The Cardiff School of ... the reasons for poor focussing among children with Downs syndrome. ... study who adopted bifocals to ease difficulties in focusing on ...
... April 29 BioElectronics,Corporation, (Pink Sheets: BIEL), announced ... the ActiPatch products to the Italian market. TSS ... both pharmacies,and consumers in Italy. TSS Medical is ... and is headquartered in Torino, Italy. Over,10,000 ActiPatch ...
... ... Characteristics of New Drugs, BOSTON, April 29 ... provider of commercial open-source "R",software for computational statistics, today released ... Quad-Core AMD,Systems," a study conducted in partnership with Pfizer on ...
... get them at the wrong time, CDC study finds , , ... more than a quarter of American toddlers may be under-vaccinated. ... months found that missed doses account for about two-thirds of ... issue, according to a study conducted by the U.S. Centers ...
... HCA announces the,following Webcast:, What: ... 9:00am CT, Where: http://www.videonewswire.com/event.asp?id=47214 , How: ... on to the web at the ... to participate during the live webcast, the call will,be archived on the ...
... management expertise to executive role, SEATTLE, April ... the appointment of John Havard as the company,s ... 21 years experience,to the Stratos team of product ... as some of the best talent,in complex technology ...
Cached Medicine News:Health News:A life 'lens' ordinary 2Health News:BioElectronics Corporation Announces New Website for Italian Market 2Health News:BioElectronics Corporation Announces New Website for Italian Market 3Health News:Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline 2Health News:Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline 3Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 2Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 3Health News:Stratos Product Development Welcomes Back John Havard as Vice President of Engineering 2
(Date:9/2/2014)... 2, 2014   Intrexon Corporation (NYSE: ... announced that it has entered into an Exclusive Channel ... of Sanofi (EURONEXT: SAN and NYSE: SNY ... specific family of its marketed Active Pharmaceutical Ingredients (APIs) ... . This collaboration will leverage Intrexon,s proprietary technology ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 Cepheid ... Flu/RSV XC, an on-demand molecular test for ... Flu B, and differentiation of RSV infection. The ... under the European Directive on In Vitro ... of tests available to eighteen. Xpert Flu/RSV XC runs ...
(Date:9/2/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... today announced that the Company,s management will participate in the ... Global Healthcare Conference, to be held at the Grand Hyatt ... Morgan Stanley Asia Pacific Healthcare Day, to be held at ... Aegis Healthcare & Technology Conference, to be held at the ...
Breaking Medicine Technology:Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4Sinovac to Participate in Upcoming Investor Conferences 2
... VirtualScopics, Inc. (Nasdaq: VSCP ), a leading provider of ... balance (the amount remaining to be recognized from its active ... the clinical research industry), exceeds $35 million which compares to ... greater than 90% increase. The average duration of the studies ...
... Sparta Systems, Inc., the maker of TrackWise® software ... compliance solutions, today announced that Ascent Healthcare Solutions, ... has selected its TrackWise Enterprise Quality Management System ... compliance with industry regulations. Ascent will deploy ...
Cached Medicine Technology:VirtualScopics' Project Balance Exceeds a Record $35 Million 2VirtualScopics' Project Balance Exceeds a Record $35 Million 3Leading Medical Device Provider Chooses TrackWise(R) Software to Optimize Customer Complaint Handling 2Leading Medical Device Provider Chooses TrackWise(R) Software to Optimize Customer Complaint Handling 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: